SCHEMBL2602810

SCHEMBL2602810

CC1CNCCCO1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11917611 1.00
SCHEMBL26579320 1.00
Hydrochloric Acid SCHEMBL537266 0.98
SCHEMBL29294181 0.93
SCHEMBL8722591 0.85 SSTR4 (0.37)
SCHEMBL16695 0.84
SCHEMBL2303916 0.84
SCHEMBL1771223 0.84
SCHEMBL6023366 0.84
Hydrochloric Acid SCHEMBL2771470 0.82

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250140352-A1 SIMPLIFIED COMPOUND IDENTIFICATION DH TECHNOLOGIES DEVELOPMENT PTE. LTD. (SG) 2025-05-01 US disclosed
US-20250019377-A1 1, 4-OXAZEPANE DERIVATIVES AND USES THEREOF JACOBIO PHARMACEUTICALS CO., LTD. (CN) 2025-01-16 US disclosed
US-20240409555-A1 CYANO CYCLOBUTYL COMPOUNDS FOR CBL-B INHIBITION AND USES THEREOF NURIX THERAPEUTICS, INC. 2024-12-12 US disclosed
CN-114206855-B Cyanocyclobutyl compounds for Cbl-b inhibition and application thereof 紐力克斯治疗公司 2024-11-26 CN disclosed
US-20240279241-A1 PYRIDO[4,3-D]PYRIMIDINE COMPOUNDS CAPABLE OF INHIBITING KRAS MUTANT PROTEINS REDX PHARMA PLC (GB) 2024-08-22 US disclosed
US-12049471-B2 Cyano cyclobutyl compounds for Cbl-b inhibition and uses thereof NURIX THERAPEUTICS, INC. (US) 2024-07-30 US disclosed
EP-4400497-A1 3CLPRO PROTEASE INHIBITOR Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. (CN) 2024-07-17 EP disclosed
EP-4347589-A2 PYRIDO[4,3-D]PYRIMIDINE COMPOUNDS CAPABLE OF INHIBITING KRAS MUTANT PROTEINS Redx Pharma Plc (GB) 2024-04-10 EP disclosed
WO-2024026433-A2 NOVEL DPP1 INHIBITORS AND USES THEREOF INSMED INCORPORATED (US) 2024-02-01 WO disclosed
CN-117460730-A Pyrido [4,3-D ] pyrimidine compounds capable of inhibiting KRAS muteins 莱德克斯制药公共有限公司 2024-01-26 CN disclosed
US-8093244-B2 Heteroaryl urea derivatives useful for inhibiting CHK1 ICOS CORPORATION (US) 2012-01-10 US disclosed
US-8093244-B2 Heteroaryl urea derivatives useful for inhibiting CHK1 ICOS CORPORATION (US) 2012-01-10 US disclosed
EP-2330105-A1 Heteroaryl urea derivatives useful for inhibiting CHK1 ICOS Corporation (US) 2011-06-08 EP disclosed
WO-2010114179-A1 3-[1,4]OXAZEPANE-4-PYRIMIDONE DERIVATIVES MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-10-07 WO disclosed
WO-2010077915-A1 NOVEL COMPOUNDS USEFUL AS CC CHEMOKINE RECEPTOR LIGANDS FOREST LABORATORIES HOLDINGS LIMITED (BM) 2010-07-08 WO disclosed
US-20100022512-A1 COMPOSITIONS OF CHK1 INHIBITORS AND CYCLODEXTRIN WISDOM WENDY A 2010-01-28 US disclosed
US-20100022512-A1 COMPOSITIONS OF CHK1 INHIBITORS AND CYCLODEXTRIN WISDOM WENDY A 2010-01-28 US disclosed
US-20090143357-A1 HETEROARYL UREA DERIVATIVES USEFUL FOR INHIBITING CHK1 ICOS CORPORATION (US) 2009-06-04 US disclosed
US-20090143357-A1 HETEROARYL UREA DERIVATIVES USEFUL FOR INHIBITING CHK1 ICOS CORPORATION (US) 2009-06-04 US disclosed
WO-2008067027-A2 COMPOSITIONS OF CHKL INHIBITORS AND CYCLODEXTRIN ICOS CORPORATION (US) 2008-06-05 WO disclosed